Table 1 Demographic, study product use, and patient impression of change analyses for patients who completed the open-label stage of a high-cannabidiol (CBD) study product for anxiety.

Demographics	Patients (n = 14)
Demographics	n (%) or Mean ± SD	Minimum	Maximum
Gender identity
Female	11 (78.6%)	-	-
Male	3 (21.4%)	-	-
Age	41.36 ± 16.89	22	64
Estimated IQ (WASI)	119.36 ± 5.51	106	129
Body mass index (BMI)	25.93 ± 4.07	20.52	34.54
Race
White	12 (85.7%)	-	-
Black	2 (14.3%)	-	-
Past cannabis use
Cannabis naïve^a	5 (35.7%)	-	-
Past light use^b	6 (42.9%)	-	-
Past frequent use^c	3 (21.4%)	-	-
Abstinence from cannabis (yrs)^d	14.44 ± 13.65	3	37
High-cannabidiol (CBD) study product use
Treatment days	31.07 ± 3.67	27	37
Product use (mL/day)	3.48 ± 0.60	2.32	4.70
Exposure to specific cannabinoids^e
Cannabidiol (CBD; mg/day)	34.73 ± 6.03	23.13	46.84
Δ9-Tetrahydrocannabinol (THC; mg/day)	0.80 ± 0.14	0.53	1.08
Cannabichromene (CBC; mg/day)	0.97 ± 0.17	0.65	1.32
Cannabigerol (CBG; mg/day)	0.38 ± 0.07	0.26	0.52
Cannabinol (CBN; mg/day)	0.21 ± 0.04	0.14	0.28
Patient global impression of change (PGIC)	Median (IQR)
PGIC after 4 weeks of treatment	6 (1.25)	4	6

Abbreviations: IQR interquartile range, WASI Wechsler Abbreviated Scale of Intelligence.
^aCannabis naïve at baseline was defined as ≤15 lifetime uses & <1 use/month.
^bPast light cannabis use was defined as a previous period of ≥1 use/month & ≤2 uses/week.
^cPast frequent cannabis use was defined as a previous period of ≥3 uses/week.
^dOnly patients with a history of past cannabis use (n = 9) reported years of abstinence.
^eThe study product was also assessed for cannabidiolic acid (CBDa), cannabidivarin (CBDV), cannabigerolic acid (CBGa), tetrahydrocannabinolic acid (THCa), and tetrahydrocannabivarin (THCV), which were not present above the limit of detection.

Quick links

Search